Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Adaptimmune Therapeutics: Q3 Earnings Insights


Benzinga | Nov 4, 2021 08:09AM EDT

Adaptimmune Therapeutics: Q3 Earnings Insights



Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM.

Here's what investors need to know about the announcement.

Earnings

Adaptimmune Therapeutics their estimated earnings by 15.38%, reporting an EPS of $-0.3 versus an estimate of $-0.26, which surprised analysts.

Revenue was up $10,000 from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.0, which was followed by a 3.48% increase in the share price the next day.

Here's a look at Adaptimmune Therapeutics's past performance:



Quarter Q2 2021 Q1 2021 Q4 2020 Q3 2020EPS Estimate -0.24 -0.25 -0.23 -0.25EPS Actual -0.24 -0.24 -0.24 -0.24Revenue Estimate 1.36M 1.83M 1.98M 870.00KRevenue Actual 3.10M 434.00K 1.50M 1.19M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC